Ana Rodríguez Ramos

Ms. Ana Rodríguez Ramos

Universidad de Cantabria – IDIVAL, Santander, Spain
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JSJose Manuel Sánchez-Maldonado
Jose Manuel Sánchez-Maldonado
MBManuel Martinez Bueno
Manuel Martinez Bueno
HCHelena Canhao
Helena Canhao
RHRob ter Horst
Rob ter Horst
SMSonia Muñoz-Peña
Sonia Muñoz-Peña
Juan SainzJuan Sainz
Juan Sainz
This study sought to evaluate the association of 28 single nucleotide polymorphisms (SNPs) within NFKB and inflammasome pathway genes with the risk of rheumatoid arthritis (RA) and response to TNF inhibitors (TNFi). We conducted a case-control study in a European population of 1194 RA patients and 1328 healthy controls. The association of potentially interesting markers was validated with data from the DANBIO (695 RA patients and 978 healthy controls) and DREAM (882 RA patients) registries. The meta-analysis of our data with those from the DANBIO registry confirmed that anti-citrullinated protein antibodies (ACPA)-positive subjects carrying the NFKB2rs11574851T allele had a significantly increased risk of developing RA (PMeta_ACPA + = 0.0006) whereas no significant effect was found in ACPA-negative individuals (PMeta_ACPA− = 0.35). An ACPA-stratified haplotype analysis including both cohorts (n = 4210) confirmed that ACPA-positive subjects carrying the NFKB2TT haplotype had an increased risk of RA (OR = 1.39, P = 0.0042) whereas no effect was found in ACPA-negative subjects (OR = 1.04, P = 0.82). The meta-analysis of our data with those from the DANBIO and DREAM registries also revealed a suggestive association of the NFKB2rs1056890 SNP with larger changes in DAS28 (OR = 1.18, P = 0.007). Functional experiments showed that peripheral blood mononuclear cells from carriers of the NFKB2rs1005044C allele (in LD with the rs1056890, r2 = 1.00) showed increased production of IL10 after stimulation with LPS (P = 0.0026). These results provide first evidence of a role of the NFKB2 locus in modulating the risk of RA in an ACPA-dependent manner and suggest its implication in determining the response to TNFi. Additional studies are now warranted to further validate these findings.

Verified
Journal Article
Open access
PDF file
Ana Rodríguez RamosAna Rodríguez Ramos
Ana Rodríguez Ramos
LMLaura Marín
Laura Marín
NINerea Iturrioz-Rodríguez
Nerea Iturrioz-Rodríguez
EPEsperanza Padín-González
Esperanza Padín-González
LHLorea García Hevia
Lorea García Hevia
MFMónica L Fanarraga
Mónica L Fanarraga
There are many nanoencapsulation systems available today. Among all these, mesoporous silica particles (MSPs) have received great attention in the last few years. Their large surface-to-volume ratio, biocompatibility, and versatility allow the encapsulation of a wide variety of drugs inside their pores. However, their chemical instability in biological fluids is a handicap to program the precise release of the therapeutic compounds. Taking advantage of the dissolving capacity of silica, in this study, we generate hollow capsules using MSPs as transitory sacrificial templates. We show how, upon MSP coating with different polyelectrolytes or proteins, fully customized hollow shells can be produced. These capsules are biocompatible, flexible, and biodegradable, and can be decorated with nanoparticles or carbon nanotubes to endow the systems with supplementary intrinsic properties. We also fill the capsules with a fluorescent dye to demonstrate intracellular compound release. Finally, we document how fluorescent polymeric capsules are engulfed by cells, releasing their encapsulated agent during the first 96 h. In summary, here, we describe how to assemble a highly versatile encapsulation structure based on silica mesoporous cores that are completely removed from the final polymeric capsule system. These drug encapsulation systems are highly customizable and have great versatility as they can be made using silica cores of different sizes and multiple coatings. This provides capsules with unique programmable attributes that are fully customizable according to the specific needs of each disease or target tissue for the development of nanocarriers in personalized medicine.

15 October 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JSJose M. Sánchez-Maldonado
Jose M. Sánchez-Maldonado
RCRafael Cáliz
Rafael Cáliz
LCLuz Canet
Luz Canet
RHRob ter Horst
Rob ter Horst
OBOlivier Bakker
Olivier Bakker
Juan SainzJuan Sainz
Juan Sainz
Here, we assessed whether 41 SNPs within steroid hormone genes associated with erosive disease. The most relevant finding was the rheumatoid factor (RF)-specific effect of the CYP1B1, CYP2C9, ESR2, FcγR3A, and SHBG SNPs to modulate the risk of bone erosions (P = 0.004, 0.0007, 0.0002, 0.013 and 0.015) that was confirmed through meta-analysis of our data with those from the DREAM registry (P = 0.000081, 0.0022, 0.00074, 0.0067 and 0.0087, respectively). Mechanistically, we also found a gender-specific correlation of the CYP2C9rs1799853T/T genotype with serum vitamin D3 levels (P = 0.00085) and a modest effect on IL1β levels after stimulation of PBMCs or blood with LPS and PHA (P = 0.0057 and P = 0.0058). An overall haplotype analysis also showed an association of 3 ESR1 haplotypes with a reduced risk of erosive arthritis (P = 0.009, P = 0.002, and P = 0.002). Furthermore, we observed that the ESR2, ESR1 and FcγR3A SNPs influenced the immune response after stimulation of PBMCs or macrophages with LPS or Pam3Cys (P = 0.002, 0.0008, 0.0011 and 1.97•10−7). Finally, we found that a model built with steroid hormone-related SNPs significantly improved the prediction of erosive disease in seropositive patients (PRF+ = 2.46•10−8) whereas no prediction was detected in seronegative patients (PRF− = 0.36). Although the predictive ability of the model was substantially lower in the replication population (PRF+ = 0.014), we could confirm that CYP1B1 and CYP2C9 SNPs help to predict erosive disease in seropositive patients. These results are the first to suggest a RF-specific association of steroid hormone-related polymorphisms with erosive disease.

5 October 2018 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
LCLuz M. Canet
Luz M. Canet
JSJose M. Sánchez-Maldonado
Jose M. Sánchez-Maldonado
RCRafael Cáliz
Rafael Cáliz
Ana Rodríguez RamosAna Rodríguez Ramos
Ana Rodríguez Ramos
CLCarmen B. Lupiañez
Carmen B. Lupiañez
Juan SainzJuan Sainz
Juan Sainz

13 October 2025 in PLOS Genetics
Verified
Journal Article
Open access
CNCaroline Nunes-Xavier
Caroline Nunes-Xavier
MPMercè Pallarès-Sastre
Mercè Pallarès-Sastre
Ana Rodríguez RamosAna Rodríguez Ramos
Ana Rodríguez Ramos
SBSonia Bañuelos
Sonia Bañuelos
ICIrune Cortajarena
Irune Cortajarena
Rafael PulidoRafael Pulido
Rafael Pulido
Germline variants in the CTNNB1 gene, encoding β-catenin protein, cause severe neurodevelopmental alterations manifested early in the infancy, and define the CTNNB1 syndrome. Patients with CTNNB1 syndrome display heterogeneous clinical manifestations, and most of them carry CTNNB1 pathogenic nonsense or frameshift variants that generate premature termination codons (PTC). We have previously described the neuropsychological manifestations of a group of CTNNB1 syndrome patients harboring novel β-catenin variants. Here, we have analysed the molecular and functional characterization of these β-catenin variants, performed genotype-phenotype analyses, and tested for β-catenin functional reconstitution. We describe a complex variety of N-terminal and C-terminal truncated β-catenin proteoforms generated by PTC. Protein stability of truncated proteoforms was variable, as indicated by their expression levels and biophysical analysis, and high protein stability correlated with better patient performance in visuospatial tests. Transcriptional activity was abrogated in most of the β-catenin variants, although some specific truncations, as well as a three-residues in-frame deletion variant, retained partial transcriptional activity. Reconstitution of full-length β-catenin expression and function was achieved in specific β-catenin PTC variants by induction of translational readthrough with aminoglycosides and protein synthesis stimulators. Inhibition of β-catenin degradation by MG-132 proteasome inhibitor also resulted in partial rescue of β-catenin transcriptional activity. Our results suggest the existence of intricate patterns of truncated β-catenin proteoforms in CTNNB1 syndrome patients, which may correlate with clinical manifestations, and provide insights to increase the function of β-catenin in patients carrying CTNNB1 pathogenic variants.

30 May 2026 in Trends in Cancer
Verified
Journal Article
Open access
CNCaroline Nunes-Xavier
Caroline Nunes-Xavier
Ana Rodríguez RamosAna Rodríguez Ramos
Ana Rodríguez Ramos
Rafael PulidoRafael Pulido
Rafael Pulido
The essential role of β-catenin/CTNNB1 in cell development highlights its therapeutic potential in cancer and neurodevelopmental syndromes. Opposing functional alterations of β-catenin in these diseases reflect distinct pathogenic genetic events in CTNNB1, leading to antagonistic therapeutic approaches. A comprehensive understanding of β-catenin functions in physiology and pathology will facilitate the implementation of β-catenin/CTNNB1-based therapies.